Drug Trial Radar · NCT06265545
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
458
Planned (sponsor's estimate)
Start
Feb 22, 2024
Primary completion
Jan 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
Conditions
- AML
- Refractory
- Relapsed
Interventions
IvosidenibDrug
in arm 1
VenetoclaxDrug
in arms 2-5
GilteritinibDrug
in arm 2
HomoharringtonineDrug
in arms 4 and 7
CytarabineDrug
in arms 3 and 7
Daunorubicin/ Idarubicin /MitoxantroneDrug
in arms 3 and 7
AzacitidineDrug
in arms 1,2 , 5 and 8
LisaftoclaxDrug
in arms 7 and 8
PI3K inhibitors, histone deacetylase inhibitors, selinexor, novel liposomal drugs, and othersDrug
in arm 6
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complex response (CRc) rate (including CR and CRi)Time frame: up to 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Blood Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.